Wells Fargo & Company Cuts Arcturus Therapeutics (NASDAQ:ARCT) Price Target to $50.00
Arcturus Therapeutics (NASDAQ:ARCT – Free Report) had its price objective reduced by Wells Fargo & Company from $58.00 to $50.00 in a report released on Friday morning,Benzinga reports. They currently have an overweight rating on the biotechnology company’s stock. Other equities analysts have also recently issued reports about the stock. BTIG Research started coverage on […]
Arcturus Therapeutics (NASDAQ:ARCT – Free Report) had its price objective reduced by Wells Fargo & Company from $58.00 to $50.00 in a report released on Friday morning,Benzinga reports. They currently have an overweight rating on the biotechnology company’s stock. Other equities analysts have also recently issued reports about the stock. BTIG Research started coverage on […]
